Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen, U Chinot, O McBain, Catherine A Mau-Sørensen, M Larsen, V Barrie, M Roth, P Krieter, O Wang, K Habben, K
Lassen, U
Chinot, O
McBain, Catherine A
Mau-Sørensen, M
Larsen, V
Barrie, M
Roth, P
Krieter, O
Wang, K
Habben, K
Citations
Altmetric:
Abstract
We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical efficacy of the combination.
Description
Date
2015-02-09
Publisher
Collections
Keywords
Type
Article
Citation
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. 2015: Neuro-oncology